Cargando…

P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE-CEL) VERSUS STANDARD REGIMENS

Detalles Bibliográficos
Autores principales:	Delforge, Michel, Patel, Krina, Eliason, Laurie, Dhanda, Devender, Shi, Ling, Guo, Shien, Marshall, Thomas, Arnulf, Bertrand, Cavo, Michele, Nooka, Ajay, Manier, Salomon, Callander, Natalie, Giralt, Sergio, Einsele, Hermann, Ailawadhi, Sikander, Popa Mckiver, Mihaela, Cook, Mark, Rodríguez-Otero, Paula
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430925/ http://dx.doi.org/10.1097/01.HS9.0000970524.03100.9e

Ejemplares similares

S195: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): A KARMMA-3 ANALYSIS IN HIGH-RISK SUBGROUPS
por: Patel, Krina, et al.
Publicado: (2023)

P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY
por: Manier, Salomon, et al.
Publicado: (2023)

B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL
por: Rodríguez-Otero, P., et al.
Publicado: (2023)

P801: BASELINE AND EARLY POST-INFUSION BIOMARKERS ASSOCIATED WITH OPTIMAL RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL) IN THE KARMMA-3 STUDY OF TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA
por: Piasecki, Julia, et al.
Publicado: (2023)

P871: IDECABTAGENE VICLEUCEL (IDE-CEL) IN PATIENTS WITH AN INADEQUATE RESPONSE TO FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): RESULTS FROM KARMMA-2 COHORT 2C
por: Alsina, Melissa, et al.
Publicado: (2023)

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
por: Jagannath, Sundar, et al.
Publicado: (2021)

Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma
por: Delforge, Michel, et al.
Publicado: (2022)

P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY
por: Rodríguez-Otero, P, et al.
Publicado: (2022)

Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial
por: McGarvey, November, et al.
Publicado: (2023)

P867: TUMOR PROFILING OF IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121) PATIENTS IN KARMMA SHOWED COMPARABLE RESPONSES IN EXISTING MOLECULAR HIGH-RISK SUBSETS AND PRELIMINARY GENE SIGNATURE OF DURABLE RESPONSE
por: Martin, N., et al.
Publicado: (2022)

P19: BASELINE CORRELATES OF COMPLETE RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF THE KARMMA TRIAL
por: Rodríguez-Otero, P, et al.
Publicado: (2022)

Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma
por: Minakata, Daisuke, et al.
Publicado: (2023)

P1740: HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH IDECABTAGENE VICLEUCEL VS BELANTAMAB MAFODOTIN: A MATCHING-ADJUSTED INDIRECT COMPARISON STUDY
por: Shah, N., et al.
Publicado: (2022)

Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients
por: Sanoyan, Dilara Akhoundova, et al.
Publicado: (2023)

The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma
por: Oriol, Albert, et al.
Publicado: (2021)

Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date
por: Mann, Hashim, et al.
Publicado: (2022)

Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
por: Lee, Dae Hyun, et al.
Publicado: (2023)

Characterizing the exposure–response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma
por: Connarn, Jamie N., et al.
Publicado: (2023)

Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
por: Logue, Jennifer M., et al.
Publicado: (2022)

Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel
por: Oswald, Laura B., et al.
Publicado: (2023)

P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL
por: Mirza, Abu-Sayeef, et al.
Publicado: (2023)

RETRACTED ARTICLE: Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis
por: Parrondo, Ricardo D., et al.
Publicado: (2022)

P866: CORRELATIVE ANALYSIS TO DEFINE PATIENT PROFILES ASSOCIATED WITH MANUFACTURING AND CLINICAL ENDPOINTS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH IDECABTAGENE VICLEUCEL (BB2121)
por: Rytlewski, J., et al.
Publicado: (2022)

Case Report: Lymphodepletion followed by CAR-T cell therapy with Idecabtagen vicleucel in a patient with severe renal impairment
por: Marquard, Franziska, et al.
Publicado: (2023)

Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial
por: Lin, Yi, et al.
Publicado: (2023)

P809: BASELINE CHARACTERISTICS IDENTIFYING PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICELEUCEL (IDE-CEL; BB2121) WHO ARE AT RISK FOR SEVERE/REFRACTORY INFLAMMATORY ADVERSE EVENTS
por: Mashadi-Hossein, Afshin, et al.
Publicado: (2023)

P880: EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A SUBGROUP ANALYSIS FROM MAGNETISMM-3
por: Leleu, Xavier, et al.
Publicado: (2023)

Errors in TCE analysis.
por: Boice, J D, et al.
Publicado: (2001)

Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM
por: Jeryczynski, Georg, et al.
Publicado: (2021)

PPARα and Effects of TCE
por: Klaunig, James E., et al.
Publicado: (2007)

Meta-analyses of TCE carcinogenicity.
por: Borak, J, et al.
Publicado: (2000)

TCE treatment pasta-bilities.
por: Holton, W C
Publicado: (1999)

Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
por: Lonial, Sagar, et al.
Publicado: (2021)

P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY
por: Suvannasankha, A., et al.
Publicado: (2022)

9.05 Technology-Enabled Synthesis of Carbohydrates
por: Snyder, N.L., et al.
Publicado: (2014)

PPARα and TCE: Keshava et al. Respond
por: Keshava, Nagalakshmi, et al.
Publicado: (2007)

TCE Meta-Analyses: Wartenberg et al.'s Response.
por: Wartenberg, D, et al.
Publicado: (2000)

The Observation of the Change of TCE Caused by Different Acupuncture Stimulation
por: Huang, Tao, et al.
Publicado: (2013)

A Clearer View of TCE: Evidence Supports Autoimmune Link
por: Weinhold, Bob
Publicado: (2009)

P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN IN COMBINATION WITH A GAMMA-SECRETASE INHIBITOR (NIROGACESTAT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-5 STUDY
por: Nooka, A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_17njeqprnshhohostt0i72ca48